Killer cell actuating receptors function as costimulatory molecules on CD4+CD28(null) T cells clonally expanded in rheumatoid arthritis

Journal of Immunology

Volumn 165, Issue 2, 2000, Pages 1138-1145

  Namekawa, Takashi ^a   Snyder, Melissa R ^a   Yen, Jeng Hsien ^a   Goehring, Brenda E ^a   Leibson, Paul J ^a   Weyand, Cornelia M ^a   Goronzy, Jörg J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN RECEPTOR; IMMUNOLOGICAL ADJUVANT; KILLER ACTIVATORY RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR; PHOSPHOTYROSINE; TYROBP PROTEIN, HUMAN;

ARTICLE; CELL PROLIFERATION; CROSS LINKING; CYTOLYSIS; HUMAN; HUMAN CELL; KILLER CELL; PHOSPHORYLATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; CELL CLONE; CELL DIVISION; CYTOTOXICITY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NATURAL KILLER CELL; PATHOLOGY; PHYSIOLOGY; T LYMPHOCYTE SUBPOPULATION;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD28; ARTHRITIS, RHEUMATOID; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CLONE CELLS; CYTOTOXICITY, IMMUNOLOGIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; PHOSPHORYLATION; PHOSPHOTYROSINE; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTE SUBSETS;

EID: 0034660690     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.2.1138     Document Type: Article

References (45)

1. + cells with a limited alloreactive T cell receptor repertoire. J. Immunol. 143:2783.
2. + T cells in severe rheumatoid arthritis. Arthritis Rheum. 40:1106.
3. - T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J. Clin. Invest. 97:2027.
4. Waase, I., C. Kayser, P. J. Carlson, J. J. Goronzy, and C. M. Weyand. 1996. Oligoclonal T cell proliferation in patients with rheumatoid arthritis and their unaffected siblings. Arthritis Rheum. 39:904.
5. Miller, G., G., T. Nepom, M. B. Reich, and J. W. Thomas. 1993. Autoreactive T cells from a type I diabetic recognize multiple class II products. Hum. Immunol. 36:219.
6. + human T cells: activation requirements and association with HLA-DR alleles. J. Immunol. 157:4771.
7. - T cells in rheumatoid arthritis. Mol. Med. 2:608.
8. Weyand, C. M., and J. J. Goronzy. 1997. The molecular basis of rheumatoid arthritis. J. Mol. Med. 75:772.
9. Goronzy, J. J., A. Zettl, and C. M. Weyand. 1998. T cell receptor repertoire in rheumaloid arthritis. Int. Rev. Immunol. 17:339.
10. - T cells. Eur. J. Immunol. 27:1082.
11. Namekawa, T., U. G. Wagner, J. J. Goronzy, and C. M. Weyand. 1998. Functional subsets of CD4 T cells in rheumatoid synovitis. Arthritis Rheum. 41:2108.
12. Yokoyama, W. M. 1998. Natural killer cell receptors. Curr. Opin. Immunol. 10:298.
13. Lanier, L. L., B. Corliss, and J. H. Phillips. 1997. Arousal and inhibition of human NK cells. Immunol. Rev. 155:145.
14. Moretta, A., and L. Moretta. 1997. HLA class 1 specific inhibitory receptors. Curr. Opin. Immunol. 9:694.
15. Ryan, J. C., and W. E. Seaman. 1997. Divergent functions of lectin-like receptors on NK cells. Immunol. Rev. 155:79.
16. Long, E. O. 1999. Regulation of immune responses through inhibitory receptors. Annu. Rev. Immunol. 17:875.
17. Biassoni, R., C. Cantoni, M. Falco, S. Verdiani, C. Bottino, M. Vitale, R. Conte, A. Poggi, A. Moretta, and L. Moretta. 1996. The human leukocyte antigen (HLA)-C-specific "activatory" or "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions. J. Exp. Med. 183:645.
18. Colonna, M., and J. Samaridis. 1995. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 268:405.
19. Wagtmann, N., R. Biassoni, C. Cantoni, S. Verdiani, M. S. Malnati, M. Vitale, C. Bottino, L. Moretta, A. Moretta, and E. O. Long. 1995. Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra-and intracellular domains. Immunity 2:439.
20. Brooks, A. G., P. E. Posch, C. J. Scorzelli, F. Borrego, and J. E. Coligan. 1997. NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor. J. Exp. Med. 185:795.
21. Carretero, M., C. Cantoni, T. Bellon, C. Bottino, R. Biassoni, A. Rodriguez, J. J. Perez-Villar, L. Moretta, A. Moretta, and M. Lopez-Botet. 1997. The CD94 and NKG2-A C-type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I molecules. Eur. J. Immunol. 27:563.
22. Lee, N., M. Llano, M. Carretero, A. Ishitani, F. Navarro, M. Lopez-Botet, and D. E. Geraghty. 1998. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl. Acad. Sci. USA 95:5199.
23. Braud, V. M., D. S. Allan, C. A. O'Callaghan, K. Soderstrom, A. D'Andrea, G. S. Ogg, S. Lazetic, N. T. Young, J. I. Bell, J. H. Phillips, et al. 1998. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391:795.
24. Borrego. F., M. Ulbrecht, E. H. Weiss, J. E. Coligan, and A. G. Brooks. 1998. Recognition of human histocompatibilily leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J. Exp. Med. 187:813.
25. + T lymphocyte subsets that express HLA class I-specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations. Proc. Natl. Acad. Sci. USA 93:12433.
26. Mingari, M. C., M. Ponte, C. Cantoni, C. Vitale, F. Schiavetti, S. Bertone, R. Bellomo, A. T. Cappai, and R. Biassoni. 1997. HLA-class I-specific inhibitory receptors in human cytolytic T lymphocytes: molecular characterization, distribution in lymphoid tissues and co-expression by individual T cells. Int. Immunol 9:485.
27. Phillips, J. H.. J. E. Gumperz, P. Parham, and L. L. Lanier. 1995. Superantigen-dependent, cell-mediated cytotoxicity inhibited by MHC class I receptors on T lymphocytes. Science 268:403.
28. Arnett, F. C., S. M. Edworthy, D. A. Bloch, D. J. McShane, J. F. Fries, N. S. Cooper, L. A. Healey, S. R. Kaplan, M. H. Liang, and H. S. Luthra. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31 :315.
29. + T cells in rheumatoid arthritis. J. Clin. Invest. 94:2068.
30. Windebank, K. P., R. T. Abraham, G. Powis, R. A. Olsen, T. J. Barna, and P. J. Leibson. 1988. Signal transduction during human natural killer cell activation: inositol phosphate generation and regulation by cyclic AMP. J. Immunol. 141:3951
31. Uhrberg, M., N. M. Valiante, B. P. Shum, H. G. Shilling, K. Lienert-Weidenbach, B. Corliss, D. Tyan, L. L. Lanier, and P. Parham. 1997. Human diversity in killer cell inhibitory receptor genes. Immunity 7:753.
32. Valiante. N. M., M. Uhrberg, H. G. Shilling, K. Lienert-Weidenbach, K. L. Arnett, A. D'Andrea, J. H. Phillips, L. L. Lanier, and P. Parham. 1997. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7:739.
33. Brumbaugh, K. M., J. J. Perez-Villar, C. J. Dick, R. A. Schoon, M. Lopez-Botet, and P. J. Leibson. 1996. Clonotypic differences in signaling from CD94 (kp43) on NK cells lead to divergent cellular responses. J. Immunol. 157:2804.
34. Sleffens, U., Y. Vyas, B. Dupont, and A. Selvakumar. 1998. Nucleotide and amino acid sequence alignment for human killer cell inhibitory receptors (KIR), 1998. Tissue Antigens 51:398.
35. Mandelboim, O., H. T. Reyburn, E. G. Sheu, M. Vales-Gomez, D. M. Davis, L. Pazmany, and J. L. Strominger. 1997. The binding site of NK receptors on HLA-C molecules. Immunity 6:341.
36. Lanier, L. L., B. C. Corliss, J. Wu, C. Lcong, and J. H. Phillips. 1998. Immunoreceplor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 391:703.
37. McVicar, D. W., L. S. Taylor, P. Gosselin, J. Willette-Brown, A. I. Mikhael, R. L. Geahlen, M. C. Nakamura, P. Linnemeyer, W. E. Seaman, S. K. Anderson, et al. 1998. DAP12-mediated signal transduction in natural killer cells: a dominant role for the Syk protein-tyrosine kinase. J Biol. Chem. 273:32934.
38. Rittner, H. L., A. Zettl, M. C. Jendro, P. Bartz-Bazzanella, J. J. Goronzy, and C. M. Weyand. 1997. Multiple mechanisms support oligoclonal T cell expansion in rheumatoid sytiovitis. Mol. Med. 3:452.
39. Karre, K., H. G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319:675.
40. + T cells. Proc. Natl. Acad. Sci. USA 95:1172.
41. Mingari, M. C., A. Moretta, and L. Moretta. 1998. Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses. Immunol. Today 19:153.
42. Mandelboim, O., D. M. Davis, H. T. Reyburn, M. Vales-Gomez, E. G. Sheu, L. Pazmany, and J. L. Strominger. 3996. Enhancement of class II-restricted T cell responses by costimulatory NK receptors for class I MHC proteins. Science 274: 2097.
43. Bendelac. A., M. N. Rivera, S. H. Park, and J. H. Roark. 1997. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu. Rev. Immunol. 15:535.
44. - T cells. J. Exp. Med. 186: 109.
45. Vallejo, A. N., J. C. Brandes, C. M. Weyand, and J. J. Goronzy. 1999. Modulation of CD28 expression: distinct regulatory pathways during activation and replicative senescence. J. Immunol. 162:6572.